TargTex
TargTex is a drug development company focused on creating localized therapies for hard-to-treat tumors, particularly Glioblastoma. Their lead product is a perioperative hydrogel that delivers a drug targeting a highly selective and unexplored target in Glioblastoma, designed as an adjunct to surgery. The company uses a novel approach to identify promising targets overexpressed in cancers with significant unmet needs. TargTex collaborates with top-tier institutions worldwide and aims to develop clinical candidates for various oncological indications, starting with Glioblastoma. They have received orphan drug designation from the FDA for their product TTX101 and are integrating AI and quantitative image analysis to support treatment assessment and predictive response markers development. The company is based in Portugal and has attracted significant funding and partnerships to advance its innovative therapies.
TargTex
TargTex is a drug development company focused on creating localized therapies for hard-to-treat tumors, particularly Glioblastoma. Their lead product is a perioperative hydrogel that delivers a drug targeting a highly selective and unexplored target in Glioblastoma, designed as an adjunct to surgery. The company uses a novel approach to identify promising targets overexpressed in cancers with significant unmet needs. TargTex collaborates with top-tier institutions worldwide and aims to develop clinical candidates for various oncological indications, starting with Glioblastoma. They have received orphan drug designation from the FDA for their product TTX101 and are integrating AI and quantitative image analysis to support treatment assessment and predictive response markers development. The company is based in Portugal and has attracted significant funding and partnerships to advance its innovative therapies.
TL;DR
Headquarters: Torres Vedras and Lisbon, Portugal
Founded: 2019
Focus: Localized perioperative hydrogel therapies for malignant gliomas (lead: TTX101)
Regulatory milestone: FDA orphan drug designation for TTX101
Funding signal: Seed + seed-extension including €2M from Basi; investor Portugal Ventures
Company Overview
Problem Domain
Treatment of malignant gliomas, including glioblastoma
Founded
2019
Industry
Biotechnology
Funding Track Record
€2M
Seed-extension investment announced February 14, 2022.
Investor Signal
“Portugal Ventures; European Innovation Council”